Skip to main content
. 2021 Sep 23;4(4):888–902. doi: 10.20517/cdr.2021.44

Figure 1.

Figure 1

Resistance to bortezomib results in heterogeneous expression of histone deacetylases (HDACs). (A) Myeloma cells (RMPI-8226wt and Kas6wt) and resistant counterparts (RPMI-8226v10r and Kas6v10r) were treated with various concentrations of bortezomib (10, 50, 100 nM) for 24 h, and cell viability was measured. Viability was normalized to control treated with vehicle. (B) Expression of HDACs in myeloma cells (RMPI-8226 and Kas6) was measured by RT-PCR. Individual HDAC expression of RPMI-8226v10r and Kas6v10r was normalized to RPMI-8226wt and Kas6wt, respectively. Data was then log2 transformed, and positive numbers indicated increased expression while negative numbers indicated decreased expression in v10r cells. *Indicate significant (P < 0.05) changes in viability for (A) or transcript expression for (B).